US Patent

US11286486 — Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

Method of Use · Assigned to Alnylam Pharmaceuticals Inc · Expires 2036-07-28 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects iRNA agents that target the transthyretin (TTR) gene for treating or preventing TTR-associated diseases.

USPTO Abstract

The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3396`	—	vutrisiran-sodium

Patent Metadata

Patent number: US11286486
Jurisdiction: US
Classification: Method of Use
Expires: 2036-07-28
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.